Drug Trial Radar · NCT05649722
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
May 11, 2023
Primary completion
Apr 1, 2026
Study completion Apr 1, 2026
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Dec 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with PH-ILD.
Conditions
- Pulmonary Hypertension
- Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation PowderDrug
Oral inhalation using a capsule-based dry powder inhaler device.
PlaceboDrug
Oral placebo inhalation using a capsule-based dry powder inhaler device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)Time frame: Up to approximately 25 months
Locations
22 sites in 7 countries. Site status is shown where the registry gives one.
ARG003
Autonomus City of Buenos Aires, Buenos Aires, Argentina
ARG001
Rosario, Santa Fe Province, Argentina
AUS005
Macquarie Park, New South Wales, Australia
BEL002
Liège, Belgium
GER002
Berlin, Germany
GER012
Berlin, Germany
GER006
Heidelberg, Baden-Wurttemberg, Germany
GER004
München, Bavaria, Germany
GER010
Giessen, Hesse, Germany
GER003
Essen, North Rhine-Westphalia, Germany
GER001
Dresden, Saxony, Germany
ITA003
Naples, Italy
ITA004
Milan, Lombardy, Italy
ITA002
Monza, Lombardy, Italy
ITA001
Palermo, Sicily, Italy
ESP005
Barcelona, Spain
ESP010
Barcelona, Spain
ESP003
Palma, Balearic Islands, Spain
ESP009
Santiago de Compostela, Galicia, Spain
ESP007
Oviedo, Principality of Asturias, Spain
GBR003
Clydebank, Glasgow, United Kingdom
GBR001
Sheffield, South Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.